Citius Oncology (CTOR) Total Current Liabilities (2022 - 2026)
Citius Oncology (CTOR) posted quarterly Total Current Liabilities of $58.8 million for Q1 2026, up 18.24% year-over-year from $49.7 million in Q1 2025, and up 31.54% quarter-over-quarter from $44.7 million in Q4 2025.
Citius Oncology (CTOR) Total Current Liabilities (2022 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Total Current Liabilities for 5 consecutive years, with $58.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 18.24% year-over-year to $58.8 million; the TTM figure through Mar 2026 stood at $58.8 million (up 18.24% YoY), while the FY2025 annual figure was $49.5 million, up 51.35% from the prior year.
- Total Current Liabilities grew to $58.8 million in Q1 2026 per CTOR's latest filing, from $44.7 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $58.8 million in Q1 2026 and bottomed at $31836.0 in Q4 2022.
- Historically, Total Current Liabilities has averaged $25.8 million across 5 years, with a median of $26.9 million in 2023.
- Annual changes were most pronounced in 2023 — Total Current Liabilities jumped 6325.94% — and 2025, when it advanced 3.02%.
- Citius Oncology's Total Current Liabilities stood at $31836.0 in 2022, then surged by 6325.94% to $2.0 million in 2023, then soared by 2021.44% to $43.4 million in 2024, then gained by 3.02% to $44.7 million in 2025, then jumped by 31.54% to $58.8 million in 2026.
- Business Quant data shows CTOR's Total Current Liabilities at $58.8 million in Q1 2026, $44.7 million in Q4 2025, and $49.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.79 Bn |
| 10 | Citius Oncology | 80.25 Mn | 80.25 Mn | 1.00 Mn | 58.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.81 Mn |
| Dec 31, 2025 | 44.71 Mn |
| Sep 30, 2025 | 49.49 Mn |
| Jun 30, 2025 | 52.99 Mn |
| Mar 31, 2025 | 49.74 Mn |
| Dec 31, 2024 | 43.40 Mn |
| Sep 30, 2024 | 32.70 Mn |
| Jun 30, 2024 | 3.08 Mn |
| Mar 31, 2024 | 2.82 Mn |
| Dec 31, 2023 | 2.05 Mn |
| Sep 30, 2023 | 21.05 Mn |
| Jun 30, 2023 | 463,875.00 |
| Mar 31, 2023 | 47,780.00 |
| Dec 31, 2022 | 31,836.00 |